Last reviewed · How we verify

SSGJ-707 — Competitive Intelligence Brief

SSGJ-707 (SSGJ-707) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-1/PD-L1 inhibitor. Area: Oncology.

phase 3 PD-1/PD-L1 inhibitor PD-1 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

SSGJ-707 (SSGJ-707) — Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.. SSGJ-707 is a small molecule that targets the PD-1/PD-L1 pathway.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
SSGJ-707 TARGET SSGJ-707 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. phase 3 PD-1/PD-L1 inhibitor PD-1
Penpulimab kcqx PENPULIMAB Akeso Biopharma marketed Pd-1 2025-01-01
Tevimbra TISLELIZUMAB Beigene marketed Programmed Death Receptor-1 Blocking Antibody [EPC] Pd-1 2025-01-01
Loqtorzi TORIPALIMAB Coherus Biosciences Inc marketed Programmed Death Receptor-1 Blocking Antibody [EPC] Pd-1 2024-01-01
Unloxcyt COSIBELIMAB Checkpoint Therapeutics Inc marketed Programmed Death Ligand-1 Blocker [EPC] Pd-1 2024-01-01
Jemperli DOSTARLIMAB GSK marketed Programmed Death Receptor-1 Blocking Antibody [EPC] PD-1 2021-01-01
Libtayo CEMIPLIMAB Regeneron Pharmaceuticals marketed PD-1 2018-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-1/PD-L1 inhibitor class)

  1. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 3 drugs in this class
  2. AstraZeneca · 2 drugs in this class
  3. Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 drug in this class
  4. Hanlim Pharm. Co., Ltd. · 1 drug in this class
  5. EMD Serono · 1 drug in this class
  6. EMS · 1 drug in this class
  7. Fujian Cancer Hospital · 1 drug in this class
  8. Elixiron Immunotherapeutics (Hong Kong) Ltd. · 1 drug in this class
  9. Cellvax Therapeutics Inc · 1 drug in this class
  10. Anhui Shi, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SSGJ-707 — Competitive Intelligence Brief. https://druglandscape.com/ci/ssgj-707. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: